Last reviewed · How we verify
"Liraglutide" and "Mitiglinide"
This combination uses liraglutide (a GLP-1 receptor agonist) to enhance insulin secretion and improve glycemic control, paired with mitiglinide (a meglitinide) to stimulate rapid insulin release from pancreatic beta cells.
This combination uses liraglutide (a GLP-1 receptor agonist) to enhance insulin secretion and improve glycemic control, paired with mitiglinide (a meglitinide) to stimulate rapid insulin release from pancreatic beta cells. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | "Liraglutide" and "Mitiglinide" |
|---|---|
| Sponsor | Third Affiliated Hospital of Third Military Medical University |
| Drug class | GLP-1 receptor agonist + meglitinide combination |
| Target | GLP-1 receptor (liraglutide); ATP-sensitive potassium channel (mitiglinide) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Liraglutide activates GLP-1 receptors on pancreatic beta cells, promoting glucose-dependent insulin secretion and slowing gastric emptying. Mitiglinide acts as a rapid-acting insulin secretagogue by binding to ATP-sensitive potassium channels on beta cells, triggering quick insulin release in response to meals. Together, they provide complementary glucose-lowering effects through different mechanisms.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Hypoglycemia
- Gastrointestinal disturbance
- Headache
Key clinical trials
- Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: